GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA [Yahoo! Finance]
GeoVax Labs, Inc. (GOVX)
NASDAQ:AMEX Investor Relations:
geovax.com/contact-geovax.html
Company Research
Source: Yahoo! Finance
Study is Funded by BARDA through Project NextGen, executed through its Clinical Studies Network ATLANTA, GA - ( NewMediaWire ) - June 27, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will partner with Allucent, a global clinical research organization (CRO), to conduct a Phase 2b clinical trial of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine. GeoVax previously announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) to advance development of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine, in a Phase 2b clinical trial. The RRPV is a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under the agreement, GeoVax w
Show less
Read more
Impact Snapshot
Event Time:
GOVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOVX alerts
High impacting GeoVax Labs, Inc. news events
Weekly update
A roundup of the hottest topics
GOVX
News
- GeoVax Labs, Inc. (NASDAQ: GOVX) had its price target raised by analysts at HC Wainwright from $8.00 to $120.00. They now have a "buy" rating on the stock.MarketBeat
- GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 [Yahoo! Finance]Yahoo! Finance
- GeoVax to Present at BIO International Convention 2024 [Yahoo! Finance]Yahoo! Finance
- GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market [Yahoo! Finance]Yahoo! Finance
- GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
GOVX
Earnings
- 11/8/23 - Miss
GOVX
Sec Filings
- 6/21/24 - Form 8-K
- 6/20/24 - Form EFFECT
- 6/18/24 - Form 8-K
- GOVX's page on the SEC website